HROW Earnings Prediction
The chart below shows how HROW performed 10 days before and after its earnings report, based on data from the past quarters. Typically, HROW sees a +1.92% change in stock price 10 days leading up to the earnings, and a +11.73% change 10 days following the report. On the earnings day itself, the stock moves by -0.30%. This data can give you a slight idea of what to expect for the next quarter's release.
HROW Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
49.26M
43.75%
0.65%
Gross Margin
75.60%
7.05%
1.64%
Operating Margin
2.68%
-47.35%
-14.38%
Net Margin
-8.57%
-33.10%
-35.22%
EPS
-0.12
-7.69%
-33.33%
No Data Available
HROW Earnings Analysis
Harrow, Inc. Common Stock Corporation (HROW.O) Earnings Conference Call
Positive
Record Revenue Growth: 1. Record Revenue: Harrow reported record revenue of $49.3 million in Q3 2024, marking a 44% increase compared to the same quarter last year.
Prescription Volume Surge: 2. Strong Prescription Growth for VEVYE: VEVYE's total prescription volume increased by 55% in Q3 compared to Q2, demonstrating robust market demand.
Impressive Refill Rate: 3. High Refill Rates for VEVYE: VEVYE has achieved an impressive refill rate of over 90%, significantly higher than the previous 90% non-refill rate for dry eye prescriptions.
Market Expansion Strategy: 4. Increased Market Coverage: The number of territories covered for VEVYE increased from 51 to 61 in Q3, enhancing the product's market presence.
Unit Demand Increase: 5. Positive Performance of IHEEZO: IHEEZO experienced a 15% sequential increase in unit demand over Q2, with an impressive reorder rate of 82%.
Negative
Inventory Shortage Consequences: 1. Inventory Shortage Impact: The strong sales of VEVYE led to a temporary inventory shortage in mid-September, capping revenue potential for the third quarter, which resulted in several million dollars of lost revenue that could have met external analyst revenue guidance.
Subdued IHEEZO Demand: 2. Subdued Demand for IHEEZO: The strategic pivot to focus on the retina specialist community may have resulted in subdued demand for IHEEZO in the third quarter, as the sales team adjusted their focus, impacting immediate sales performance.
Expense Management Concerns: 3. Operating Expense Management: While the company is focused on growth, there is a concern regarding the balance of operating expenses, as any further investment in operating expenses will be tied primarily to the commercial side, potentially impacting profitability if not managed carefully.
TRIESENCE Revenue Uncertainty: 4. Delayed Revenue from TRIESENCE: The relaunch of TRIESENCE is still in its early stages, and while initial responses are positive, the company has not yet quantified expected revenue pull-through, indicating uncertainty in immediate financial performance from this product.
Seasonal Revenue Challenges: 5. Market Seasonality Effects: The company acknowledged that Q3 typically experiences weaker results due to summer seasonality, which affects surgical scheduling and overall revenue generation, indicating a recurring challenge in achieving consistent quarterly growth.
HROW FAQs
How does HROW typically perform around its earnings report dates?
Is Harrow, Inc. (HROW) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
HROW Earning Call Sentiment
Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
HROW.O
-8.86%Positive
The earnings call presents a strong financial performance with record revenue growth and optimistic future guidance. The Q&A section reinforces positive sentiment with strong demand for TRIESENCE and VEVYE, despite minor disruptions. The lack of share repurchase announcements and some regulatory risks are potential concerns, but the overall outlook with strategic agreements and market expansion is favorable. The absence of market cap data suggests a moderate impact on stock price, leading to a positive prediction.
